DongKook Pharmaceutical (Korea) Top Management

086450 Stock  KRW 15,600  150.00  0.97%   
DongKook Pharmaceutical employs about 1.1 K people. The company is managed by 24 executives with a total tenure of roughly 140 years, averaging almost 5.0 years of service per executive, having 44.0 employees per reported executive. Analysis of DongKook Pharmaceutical's management performance can provide insight into the company performance.
Heung Oh  CEO
Chief Executive Officer, Director
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in DongKook Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

DongKook Pharmaceutical Management Team Effectiveness

The company has return on total asset (ROA) of 0.0608 % which means that it generated a profit of $0.0608 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 12.717 %, meaning that it generated $12.717 on every $100 dollars invested by stockholders. DongKook Pharmaceutical's management efficiency ratios could be used to measure how well DongKook Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.

DongKook Pharmaceutical Workforce Comparison

DongKook Pharmaceutical Co is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 231,530. DongKook Pharmaceutical adds roughly 1,056 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of 0.08 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.11 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.11.

DongKook Pharmaceutical Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. DongKook Pharmaceutical Price Series Summation is a cross summation of DongKook Pharmaceutical price series and its benchmark/peer.

DongKook Pharmaceutical Notable Stakeholders

A DongKook Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DongKook Pharmaceutical often face trade-offs trying to please all of them. DongKook Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DongKook Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Heung OhChief Executive Officer, DirectorProfile
Gyeong ChaManaging DirectorProfile
Bong ChoAssistant Managing DirectorProfile
Jae ParkAssistant Managing DirectorProfile
Mok ParkManaging DirectorProfile
Se JeonAssistant Managing DirectorProfile
Gi JungManaging DirectorProfile
Byeong YooManaging DirectorProfile
Seung PyoAssistant Managing DirectorProfile
Hui KimManaging DirectorProfile
Tae KimAssistant Managing DirectorProfile
GyuJin LeeManaging ManagementProfile
HongKi KimDirector FinProfile
Gi KwonVice Chairman of the BoardProfile
HeeSoon ParkManaging MarketingProfile
YoungWook LeePres CEOProfile
BongHo ChoManaging SalesProfile
Gyu JungInternal AuditorProfile
HeungJu OhVP CEOProfile
SoonKang HongManaging PRProfile
SeIl JeonManaging SalesProfile
JoonHo SongManaging PlanningProfile
JeWon ParkManaging SalesProfile
Byeong YeoDirectorProfile

About DongKook Pharmaceutical Management Performance

The success or failure of an entity such as DongKook Pharmaceutical often depends on how effective the management is. DongKook Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DongKook management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DongKook management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea. DongKook Pharm is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of DongKook Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DongKook Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of DongKook Pharmaceutical's management manipulating its earnings.

DongKook Pharmaceutical Workforce Analysis

Traditionally, organizations such as DongKook Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DongKook Pharmaceutical within its industry.

DongKook Pharmaceutical Manpower Efficiency

Return on DongKook Pharmaceutical Manpower

Revenue Per Employee562.7M
Revenue Per Executive24.8B
Net Income Per Employee50.1M
Net Income Per Executive2.2B
Working Capital Per Employee132.1M
Working Capital Per Executive5.8B

Complementary Tools for DongKook Stock analysis

When running DongKook Pharmaceutical's price analysis, check to measure DongKook Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DongKook Pharmaceutical is operating at the current time. Most of DongKook Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of DongKook Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DongKook Pharmaceutical's price. Additionally, you may evaluate how the addition of DongKook Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account